A Priority FDA Review for Toremifene 80 mg for Bone Protection

GTx announced in a company media release that it has requested that the FDA consider its new drug application (NDA) for the use of toremifene 80 mg to prevent bone fractures in men with prostate cancer receiving androgen deprivation therapy (ADT). GTx has asked for a priority review of its application stating that “there are [...]

Bone Turnover Marker Data And Additional PSA Progression Safety Analysis For Toremifene 80 Mg Phase III ADT Clinical Trial

GTx, Inc. (Nasdaq: GTXI) has conducted a number of clinical trials using toremifene citrate in both the treatment of breast and prostate cancer. Older women and men as well as women and men being treated for both breast and prostate cancers are subject to bone loss leading to an increased risk of falls and fractures. [...]

By |2017-10-19T10:57:00-04:00October 1st, 2008